High-Throughput Optical Controlling and Recording Calcium Signal in iPSC-Derived Cardiomyocytes for Toxicity Testing and Phenotypic Drug Screening
March 31st, 2022
4.7K views
The present protocol describes all-optical control and observation of triggered cellular activity in iPSC-derived cardiomyocytes (iPSC-CMs) for high throughput drug screening and toxicity testing. Multi-parametric quantification of phenotypic patterns in time, and space, are shown. Long-term effects of drugs over hours, or sequential measurements over days, are demonstrated.
Overview
This protocol outlines a method for all-optical control and observation of cellular activity in iPSC-derived cardiomyocytes (iPSC-CMs), facilitating high-throughput drug screening and toxicity testing. It emphasizes multi-parametric quantification of phenotypic patterns over time and space, demonstrating the long-term effects of drugs.
Key Study Components
Area of Science
- Cardiomyocyte biology
- Optogenetics
- Drug screening
Background
- iPSC-derived cardiomyocytes are valuable for studying cardiac function.
- All-optical techniques enhance the ability to monitor cellular responses.
- High-throughput methods are essential for efficient drug testing.
- Understanding drug effects on cardiomyocytes can inform therapeutic strategies.
Purpose of Study
- To develop a protocol for observing cellular activity in iPSC-CMs.
- To enable high-throughput screening of drug effects.
- To assess the long-term impact of pharmacological agents on cardiomyocyte function.
Methods Used
- Preparation of multi-well plates for cell culture.
- Transduction of cells with genetically encoded calcium indicators (GECIs).
- High-content imaging for real-time observation of calcium transients.
- Analysis of drug effects on calcium signaling and cellular behavior.
Main Results
- Demonstrated successful all-optical control of iPSC-CMs.
- Identified dose-dependent effects of drugs on calcium transients.
- Showed consistent cellular behavior over time with GECIs.
- Provided insights into the impact of specific ion channel inhibitors.
Conclusions
- The protocol allows for detailed study of cardiomyocyte responses to drugs.
- It can be adapted for various cell types in functional screening.
- Findings contribute to understanding drug mechanisms in cardiac cells.
Frequently Asked Questions
What are iPSC-derived cardiomyocytes?
iPSC-derived cardiomyocytes are heart cells generated from induced pluripotent stem cells, used for studying cardiac function.
How does the all-optical method work?
The all-optical method uses light to control and observe cellular activity, allowing real-time monitoring of calcium signaling.
What is the significance of using GECIs?
GECIs enable the visualization of calcium dynamics in living cells, providing insights into cellular responses to stimuli.
Can this method be applied to other cell types?
Yes, the method can be adapted for various cell types, including neurons and pancreatic beta cells.
What are the implications of this research?
This research enhances drug discovery processes and improves understanding of cardiac drug effects, potentially leading to better therapies.
How long can the effects of drugs be observed?
The protocol allows for observation of drug effects over hours or days, providing insights into both immediate and long-term responses.
Executive Industry Relevance
This method enables high-throughput, all-optical control and real-time monitoring of calcium signaling in iPSC-derived cardiomyocytes, supporting phenotypic drug screening and cardiotoxicity assessment. By combining genetically encoded calcium indicators with optogenetic pacing, it provides multi-parametric, longitudinal phenotypic readouts that improve predictive confidence in early discovery. The approach reduces reliance on electrophysiology and fluorescent dye loading, offering a scalable, reproducible platform for de-risking ion channel targets and prioritizing compounds in cardiovascular drug discovery pipelines.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Scientific Value: Enables interrogation of therapeutic hypotheses by linking ion channel modulation to calcium transient phenotypes in a genetically tractable, human-relevant model.
- Operational Value: Supports functional target validation through dose-dependent, optically controlled perturbation and quantification of calcium dynamics.
- Predictive Value: Facilitates mechanistic de-risking of cardiotoxic liabilities by isolating specific ion channel effects (e.g., hERG, L-type calcium channel) via controlled optical pacing and indicator-specific readouts.
Screening & Assay Development
- Assay Readiness: Generates standardized, quantitative calcium transient metrics (amplitude, duration, rise/decay time, frequency) compatible with high-content imaging systems for 96-well format screening.
- Reproducibility: Enables consistent longitudinal monitoring over days or weeks post-transduction, reducing variability associated with acute dye loading or manual stimulation.
- Multiplexing Capability: Allows simultaneous assessment of subcellular calcium stores (cytosol, mitochondria, ER/SR) using spectrally separated GECIs, enriching phenotypic profiling beyond surface-level contractility.
Translational & Preclinical Research
- Disease Modeling: Supports use of patient-derived iPSC-CMs to capture genotype-phenotype relationships in inherited cardiomyopathies or channelopathies.
- Translational Continuity: Bridges discovery-phase phenotypic screening with preclinical safety assessment by providing human-relevant, mechanism-based functional readouts.
- Risk-Adjusted Advancement: Enables early identification of compounds with favorable calcium handling profiles, informing go/no-go decisions before resource-intensive preclinical studies.
Pipeline & Workflow Integration
The method integrates into early discovery workflows following target identification and preceding lead optimization, providing functional validation in a human cardiomyocyte context before preclinical commitment.
- Discovery Biology: Supports hypothesis testing by enabling all-optical control of cellular activity and real-time observation of calcium signaling dynamics in response to genetic or pharmacological perturbation.
- Screening: Delivers assay-ready, reproducible phenotypic readouts with temporal and spatial resolution, suitable for automated compound screening in multi-well formats.
- Analytics: Provides quantitative, multi-parametric outputs (peak amplitude, transient duration, rise/decay kinetics, beating frequency) that enable objective comparison of compound effects and structure-activity relationship modeling.
- Translational Research: Connects to preclinical safety assessment by modeling human cardiomyocyte responses to ion channel modulators in a genetically defined, scalable system.
- Enterprise Reuse: Establishes a reusable, standardized platform for cardiovascular target validation and phenotypic screening across projects, reducing redundant assay development.
Operational & Enterprise Impact
- Scientific Value: Increases predictive confidence in target validation by reducing mechanistic ambiguity through optically isolated, quantifiable calcium signaling readouts.
- Operational Value: Enhances reproducibility and scalability via viral transduction-based indicator expression and automated high-content imaging, minimizing well-to-well and operator variability.
- Strategic Value: Improves capital efficiency by enabling early detection of cardiotoxic risk, reducing late-stage attrition and optimizing portfolio allocation.
- Portfolio Impact: Supports risk-adjusted prioritization of compounds based on calcium handling phenotypes, aligning with safety-driven advancement criteria in cardiovascular drug discovery.
Implementation Considerations
- Requires expertise in iPSC culture, viral transduction, and high-content imaging system operation.
- Dependent on access to spectrally compatible GECIs, optogenetic actuators (e.g., channelrhodopsin-2), and LED-based illumination modules.
- Necessitates standardized protocols for indicator expression, optical pacing parameters, and calcium transient analysis across sites or teams.
- Adaptation to alternative model systems (e.g., neurons, beta cells) may require optimization of promoter specificity, indicator localization, and stimulation paradigms.
- Long-term signal stability depends on promoter choice and transgene expression levels, with potential silencing over extended culture periods.
Biopharma FAQs
Why does optical pacing improve target validation in iPSC-CMs?
Optical pacing using channelrhodopsin-2 enables precise, reproducible control of contraction frequency, isolating drug effects on calcium handling from variability in spontaneous beating. This allows consistent assessment of ion channel modulator effects on calcium transient amplitude and kinetics across wells and time points, improving data quality in screening campaigns.
How does isolating the optogenetic stimulus variable support discovery pipeline decisions?
By decoupling stimulation from contraction, researchers can attribute changes in calcium signaling directly to pharmacological or genetic interventions, reducing confounding factors. This supports clearer structure-activity relationships and more confident go/no-go decisions during lead identification based on mechanism-specific phenotypes.
What quantitative calcium transient measurements enable compound comparison?
The method quantifies peak amplitude, transient duration at 50% and 90%, rise time, decay time, and beating frequency, providing multi-parametric profiles that reflect distinct mechanisms of action. These objective, continuous readouts allow ranking of compounds by potency and selectivity in calcium handling modulation.
Why are replication requirements important for cross-functional collaboration?
Replication across wells, plates, and experimental runs ensures that observed calcium transient changes are robust and not due to technical artifacts, building confidence in assay reliability. This consistency enables toxicology, medicinal chemistry, and biology teams to align on compound risk assessments using shared, reproducible data.
What statistical analysis capabilities are required before implementing this assay?
Implementation requires the ability to analyze calcium transient features (amplitude, duration, frequency) using automated peak detection and curve fitting tools, with outputs suitable for dose-response modeling and inter-group comparisons. Software must support batch processing of 96-well plate data and export of kinetic traces for downstream statistical evaluation in discovery informatics pipelines.
Chapters in this video
0:04
Introduction
0:57
iPSC Derived Cardiomyocytes Preparation
2:28
Expression of Genetically Encoded Calcium Indicators
3:24
Image Acquisition and Functional Assays for Toxicity Test and Phenotypic Screening
5:22
Small Molecule Preparation
5:58
Imaging Processing and Analysis
6:31
Results: Imaging and Processing of Cells
9:28
Conclusion
